
In this explanatory segment, the speaker reviews a 2020 Mass General Hospital study and a 12‑month clinical trial showing that tesamorelin markedly reduces liver fat—by about 37% after a year of treatment. The reduction is linked to activation of growth‑hormone‑releasing‑hormone (GHRH) receptors, which up‑regulates the master mitochondrial biogenesis factor PGC‑1α, leading to new mitochondria formation and increased fatty‑acid oxidation. The speaker also notes that tesamorelin down‑regulates inflammatory cytokines produced by visceral fat, thereby improving hormonal health. Finally, the segment highlights emerging evidence that tesamorelin can lessen neuroinflammation and boost prefrontal cortex activity, translating into better executive function and memory in older adults.











